Aptevo Therapeutics Inc (NASDAQ:APVO) Director Fuad El-Hibri acquired 14,404 shares of the company’s stock in a transaction dated Thursday, July 18th. The stock was acquired at an average cost of $0.87 per share, with a total value of $12,531.48. Following the transaction, the director now directly owns 903,061 shares of the company’s stock, valued at $785,663.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Fuad El-Hibri also recently made the following trade(s):
- On Tuesday, July 16th, Fuad El-Hibri acquired 11,375 shares of Aptevo Therapeutics stock. The stock was acquired at an average cost of $0.85 per share, with a total value of $9,668.75.
- On Wednesday, July 10th, Fuad El-Hibri purchased 18,919 shares of Aptevo Therapeutics stock. The shares were purchased at an average cost of $0.85 per share, with a total value of $16,081.15.
APVO opened at $0.87 on Friday. The company’s fifty day moving average price is $0.86. Aptevo Therapeutics Inc has a twelve month low of $0.67 and a twelve month high of $5.80. The company has a quick ratio of 2.91, a current ratio of 3.15 and a debt-to-equity ratio of 0.60.
APVO has been the subject of a number of recent analyst reports. Piper Jaffray Companies raised their price target on shares of Aptevo Therapeutics from $4.00 to $4.50 and gave the company an “overweight” rating in a report on Monday, April 15th. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Roth Capital reaffirmed a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd. Finally, Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $7.88.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its position in shares of Aptevo Therapeutics by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock worth $1,831,000 after purchasing an additional 16,482 shares in the last quarter. Deutsche Bank AG increased its position in shares of Aptevo Therapeutics by 251.7% during the fourth quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock worth $419,000 after purchasing an additional 236,300 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Aptevo Therapeutics during the first quarter worth $33,000. 36.37% of the stock is owned by institutional investors and hedge funds.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.